Videos

Close Video

VLG.L59.00GBp0.50 (+0.85%)

52wk Low / High
40.00 / 90.00
Market Cap
£21.73m
Shares in Issue
36.83m
Earnings Per Share (TTM)
-
Current PE Ratio (TTM)
-
Div / Yield
0.04p / 0.07%

Quotes delayed, except where indicated otherwise. Currency in GBp.

Overview

Venture Life Group (AIM: VLG) is an international consumer self-care company focused on developing, manufacturing and commercializing over the counter products for the global ageing population. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group’s international distribution partners.

With its wholly owned manufacturing subsidiary in Italy, VLG aims to improve its operating leverage by adding new brands to its existing portfolio and rolling these out geographically. VLG avoids taking new technology risks, instead focusing on developing and commercialising innovative products for the international consumer healthcare market. Utilising its global network of intermediaries, the company selects product opportunities that perform well regionally and rolls them out into further geographies. This limits development and regulatory risk whilst enabling strong growth.

The Group’s own branded products are currently sold or partnered in over 40 countries. The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing.

www.venture-life.com

Directors

  • Dr Lynn Drummond (NE Chair): NE Chair Infirst Healthcare Ltd, NED RPC Group. Ex MD Investment Banking Rothschild.
  • Jerry Randall (CEO): Co-founder. Ex CFO Sinclair Pharma Plc. Ex corp fin at KPMG.
  • Adrian Crockett (CFO): formerly FD Abbott Diabetes Care Ltd, a division of Abbott Laboratories
  • Sharon Collins (Commercial Dir): Co-founder. 15 yrs sector experience, 5yrs Sinclair Pharma Plc.
  • Gianluca Braguti (Dir, Manufacturing): Founder Biokosmes.
  • Peter Bream (NED): Current directorships at the Alcontrol Group. Significant intn’l business experience, including China.

Financials

P&L2016
£~000
2015
£~000
Revenue14,2809,077
Cost of sales(8,789)(6,073)
Gross profit5,4913,004
Operating Loss(465)(1,694)
Loss for the year(1,369)(1,761)
BALANCE SHEET2016
£~000
2015
£~000
Cash & cash equivalents1,9982,857
Total assets27,34621,917

Peer Group

  • Alliance Pharma (AIM: APH): UK based pharma
  • Sinclair Pharma (LSE: SPH): International pharma Co focussing on aesthetics, wound care & skin care
  • Futura Medical (AIM: FUM): UK based pharma
  • Plethora Solutions (AIM: PLE): focuses on commercialising FORTACIN
  • Church & Dwight (NYSE: CHD): produces sodium bicarbonate and sodium bicarbonate products

Major Shareholders

Management

  • Gianluca Braguti – 19.23%
  • Jerry Randall – 10.67%
  • Sharon Collins – 4.30%

Others

  • JO Hambro – 11.91%
  • Aviva Investors – 7.85%
  • Quilter Cheviot – 6.14%
  • Jarvis Investment – 3.4%
  • Vestra Wealth – 2.49%

Macro Indicators

NHS – “Some Facts & Stats about Self Care”
“57 million GP consultations every year involve minor ailments which can be handled through self-care.”

Media coverage

Digital Look (25 Mar 2015)
“Venture Life trims losses as ageing population treatments gain traction.”

Stockmarketwire (16 Mar 2015)
“VLG to sell a number of trademarks for dermatology product.”

This is Money (Apr 2014)
“SMALL CAP SHARE IDEAS: ‘Venture Life sees future in growing old.'”

Broker Coverage

Panmure Gordon (Mar 2017)
“VLG has announced results for FY to 31 Dec 2016 and while investors got a good flavour of the FY16 performance in the Jan trading update, we think the performance speaks for itself. Prior to January we’d been looking for £14m top-line for the year, VLG has come in with £14.3m (+57%), adj EBITDA £0.8m (vs PGe adj EBITDA £0.6m), gross margin up, operational leverage kicking in, UltraDEX ticking along very nicely, new key hires. We consider VLG to be a well-positioned growth business taking advantage of a well-developed product platform, with high-quality execution.”

Northland Capital (Mar 2017)
“Venture Life produced a strong set of results. In 2016 the Company has: integrated the UltraDEX brand; signed thirteen new long term distribution agreements; enabled nine new product launches by partners; developed three new products; among other achievements. Importantly, the Group achieved maiden reported EBITDA (Adj.) profitability. With 2017 off to a strong start, we estimate that the company will continue to benefit from further operational gearing going forward.”

 

Submit your details to be kept up to date with announcements regarding Venture Life Group plc

We have a strict data protection policy and will not share your details with external parties.